FDA Brief

FDA warning letters

A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.

35 letters match. Newest first.

  1. Tianjin Healthcare Medical Technology Co., Ltd.

    Chinese API maker refused FDA records requests, and all its drugs now face a US import alert.

    High risk
  2. OrganiCare, LLC / OrganiCare Nature’s Science, LLC

    FDA told OrganiCare of Austin, Texas that its HClear for him and FemiClear Genital Herpes Symptoms ointments are unapproved new drugs.

    High risk
  3. TCI Co., Ltd BioCosme PABP BRANCH

    FDA warns Taiwan OTC drug contract manufacturer TCI BioCosme over CGMP violations, including incomplete release and ingredient testing.

    High risk
  4. Babikian Healthcare Products CJSC

    FDA warns Babikian Healthcare Products over manufacturing quality failures for over-the-counter drugs, including missing identity and finished-product testing.

    High risk
  5. Dabur India Limited

    FDA cites Dabur India for falsified records, incomplete lab data, and inadequate cleaning and process validation for over-the-counter drugs.

    High risk
  6. Yangzhou Hongshengding Chemical Co., Ltd.

    Yangzhou Hongshengding Chemical refused FDA records requests for its over-the-counter drugs, leading to an import alert.

    High risk
  7. Laboratorios Dr. Collado S.A.

    FDA warns Laboratorios Dr. Collado over inadequate asbestos testing and quality oversight for talc-containing over-the-counter drugs.

    High risk
  8. GC America, Inc.

    FDA warned GC America after an inspection found inadequate component testing, stability data, and quality oversight for its OTC drugs.

    High risk
  9. IDO Pharm Co., Ltd.

    IDO Pharm, South Korean drug manufacturer, cited for good manufacturing practice violations including unvalidated system and test methods.

    High risk
  10. Fareva Morton Grove

    FDA found microbial contamination risks and data integrity failures at Fareva Morton Grove's OTC drug manufacturing.

    High risk
  11. LiquidCapsule Manufacturing, LLC

    LiquidCapsule Manufacturing failed CGMP (current good manufacturing practice) for OTC drugs, including component identity testing and process validation failures.

    High risk
  12. Private Label Skin Care, Inc.

    FDA warned Private Label Skin Care about poor quality oversight, continued sale of impurity-affected over-the-counter drugs, and missing drug listings.

    High risk
  13. Taizhou Kangping Medical Science and Technology Co., Ltd.

    FDA warns Taizhou Kangping about over-the-counter drugs labeled sterile that were not sterilized.

    High risk
  14. Naturich Cosmetique Labs

    FDA warned Naturich Cosmetique Labs over inadequate manufacturing controls for over-the-counter topical drugs, including contaminated water and untested ingredients.

    High risk
  15. Creative Essences, Inc.

    FDA warns Creative Essences over OTC drug manufacturing failures and an unapproved antiseptic.

    High risk
  16. Dixon Investments Inc. dba ARI

    FDA cites Dixon Investments (ARI) for manufacturing-rule and unapproved/misbranded OTC aerosol drug violations.

    High risk
  17. NWL Netherlands Services B.V.

    FDA cites NWL Netherlands drug plant for inadequate microbial investigations, missing component identity testing, and weak lab data controls.

    High risk
  18. Taizhou Jingshang Cosmetics Technology Co., Ltd.

    FDA warns Taizhou Jingshang Cosmetics Technology over current good manufacturing practice failures in over-the-counter drugs, including missing identity tests for high-risk ingredients.

    High risk
  19. Aspen Pharmacare Holdings Limited

    FDA warns Aspen subsidiary over sterile OTC drug manufacturing failures including impurity testing, aseptic practices, data integrity, and environmental monitoring.

    High risk
  20. Rite-Kem Incorporated

    FDA warned Rite-Kem over inadequate current good manufacturing practice testing of over-the-counter drugs, including hand sanitizers and antimicrobial products.

    High risk
  21. Akron Formulations India Private Limited

    Akron Formulations India's over-the-counter drugs are adulterated due to manufacturing quality (CGMP) failures, including unqualified active ingredient (API) suppliers and inadequate microbial testing.

    High risk
  22. MedOffice Saglik Endustri Anonim Sirketi

    FDA warned MedOffice Saglik after an inspection found missing batch release testing and inadequate process validation for over-the-counter drugs.

    High risk
  23. Ambaya Gold Health Products, LLC

    FDA warned Ambaya Gold Health Products that website and social media claims made its supplements and silver products unapproved new drugs.

    High risk
  24. Inmar Supply Chain Solutions, LLC

    FDA found severe rodent infestation at Inmar warehouse, adulterating stored foods, over-the-counter drugs, and devices.

    High risk
  25. Kraft Drug

    Kraft Drug marketed unapproved antibiotics for aquarium fish and birds as over-the-counter drugs, FDA says.

    High risk
  26. Lex Inc.

    FDA warns Lex Inc. of Medley, Florida, that its over-the-counter drugs are adulterated because manufacturing rules were not met, including missing toxic-ingredient testing.

    High risk
  27. Amazon.com, Inc

    FDA warned Amazon that it sold four unapproved drugs claiming to treat molluscum contagiosum, including products marketed for children.

    High risk
  28. Skyline Herbals Private Limited

    FDA warns India's Skyline Herbals after it ignored records requests for OTC drugs including toothpaste; all its drugs hit Import Alert 66-79.

    High risk
  29. Daxal Cosmetics Private Limited

    FDA warns Daxal Cosmetics for refusing records on over-the-counter drugs, including toothpaste, at risk for diethylene glycol and ethylene glycol contamination.

    High risk
  30. Eco Lips, Inc.

    FDA warned Eco Lips, Inc. that its over-the-counter sunscreen drug products had serious manufacturing and testing failures.

    High risk
  31. Profounda, Inc.

    FDA warns Profounda about manufacturing quality failures for over-the-counter drugs, including process validation, stability, water system, and glycerin testing.

    High risk
  32. Fei Fah Medical Manufacturing Pte. Ltd.

    FDA warned Fei Fah Medical Manufacturing over inadequate stability data, unvalidated test methods, and supplier testing failures for over-the-counter drugs.

    High risk
  33. Neoteric Cosmetics, Incorporated/Scott’s Liquid Gold, Inc.

    FDA warned Neoteric Cosmetics and parent Scott's Liquid Gold that ALPHA Skin Care Dual Action Fade Cream, a hydroquinone skin lightener, is an unapproved and misbranded drug.

    Medium
  34. Dr Retter Ec Wladyslaw Retter

    FDA warns Dr Retter Ec Wladyslaw Retter over manufacturing failures for homeopathic drug cream.

    High risk
  35. Gulsah Uretim Kozmetik Sanayi Anonim Sirketi

    Turkish OTC drug maker Gulsah failed to test its products and ingredients, and FDA blocked its U.S. imports.

    High risk